3 news items
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
ADPT
31 May 24
Disease (MRD) Is Associated With Improved Long-Term Outcome in Patients With Follicular Lymphoma (FL) Treated With Chemo-Immunotherapy: Results From SWOG
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
ADPT
7 May 24
Long
Adaptive Biotechnologies Names New CFO Preserves Strong Capital Position
ADPT
3 Apr 24
projects, offers long-term valuation upside.
The analyst reiterates
- Prev
- 1
- Next